(MORE) Dow Jones Newswires November 09, 2004 09:00 ET (14:00 GMT)- - 09 00 AM EST 11-09-04
=DJ Study: Sanofi-Aventis Drug Helps People Lose Weight -2
. In the two-year study, 32.8% of patients taking the 20 milligram dose of rimonabant lost 10% or more of their initial body weight, compared to 20% on the 5 milligram dose and 16.2% of those not taking the drug. The study was led by Dr. F. Xavier Pi-Sunyer, the chief of the endocrinology, diabetes and nutrition division at St. Luke's-Roosevelt Hospital in New York. He said the results showed that rimonabant "is an innovative and promising tool for the long-term management of weight" that's been associated with an increased risk of cardiovascular disease. "As the cardiovascular risk factors associated with obesity have become more manifest, it has become increasingly apparent that current approaches are insufficient," Pi-Sunyer said. About two-thirds of all Americans are overweight or obese. Doug Green, the vice president of regulatory affairs for Sanofi-Aventis, said the company plans to file for Food and Drug Administration and European regulatory approval of rimonabant during the second quarter of 2005. The study also showed that waist circumference in patients treated with 20 milligrams of rimonabant was reduced about 3.1 inches, while those on the lower dose lost an average of 1.9 inches. Those in the placebo group lost about 1.5 inches. The drug also appeared to improve so-called metabolic parameters like cholesterol, triglycerides and insulin sensitivity. Researchers said the effect of rimonabant on HDL-cholesterol, triglycerides and insulin appeared to be about twice of that which would be expected from the improvement by weight-loss alone. "Good" cholesterol, or HDL cholesterol was raised by 24.5% in patients taking the higher dose of rimonabant, compared to 15.6% in those on the lower dose and 13.8% in the placebo group. One-third of patients taking the higher dose of the drug also saw metabolic syndrome reversal during the study period. Metabolic syndrome is defined as having three of five risk factors that contribute to heart disease: high blood pressure, high glucose, or blood sugar, high triglyceride levels, low levels of good cholesterol and a large waist. High blood sugar is a risk factor for developing diabetes. Pi-Sunyer said the number patients who stopped using the drug and the placebo during the study were similar, suggesting the rimonabant is well-tolerated. He said patients on the higher dose of the drug experienced more nausea and there appeared to be a "slightly higher" incidence of anxiety or depression, although the three patient groups had similar scores on a test that measured for depression.
I am not sure if the major stockholders happen to own MacDonalds, Wendy's, KFC, etc.
Sanofi has almost come out with a miracle pill that lets you lose weight, increase good cholesterol, etc. But the interest in such a drug does not seem to be there. I have no idea why this company is not in favor. Beats me.
FDA busting fraud weight loss companies. All are crooks. No drug has proven to work long term. If SNY really has the answer and it seems they do. I am damn glad to be in!http://www.nutrawize.com/medications.htm
the news is confirmed as f-ing fantastic! right? The stock was way overbought and sell on the news is what the traders will do. I am going to accumulate a position on dips and then trade this sucker to a fortune! glta hogs